2018
DOI: 10.1080/17476348.2018.1475233
|View full text |Cite
|
Sign up to set email alerts
|

Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?

Abstract: Although symptom controls in asthmatic children can be achieved through compliant use of conventional medication, some children have uncontrolled severe persistent asthma, especially if they are allergic. For these children, omalizumab (approved by the EMA and FDA in children aged > 6 years) could be a therapeutic option. However, response to omalizumab varies from one child to another. Predictive biomarkers of omalizumab effectiveness could be useful to monitor response to treatment. Area covered: The authors… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
7
0
3

Year Published

2019
2019
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(12 citation statements)
references
References 114 publications
(148 reference statements)
2
7
0
3
Order By: Relevance
“…Additionally, sECP may possibly be a valuable biomarker if measured in a larger group of younger asthmatic patients, stratified by age (0–2 years), during the critical time for lung development. It has been suggested in the literature that an isolated marker might not be sufficient in defining phenotypes of asthma in the diagnostic process 22 . Hence, in future studies, the role of sECP should be measured in conjunction with other biomarkers (eosinophil counts, exhaled nitric oxide, and urinary eosinophil protein X) to evaluate the diagnostic capabilities of inflammatory markers in childhood asthma.…”
Section: Discussionmentioning
confidence: 99%
“…Additionally, sECP may possibly be a valuable biomarker if measured in a larger group of younger asthmatic patients, stratified by age (0–2 years), during the critical time for lung development. It has been suggested in the literature that an isolated marker might not be sufficient in defining phenotypes of asthma in the diagnostic process 22 . Hence, in future studies, the role of sECP should be measured in conjunction with other biomarkers (eosinophil counts, exhaled nitric oxide, and urinary eosinophil protein X) to evaluate the diagnostic capabilities of inflammatory markers in childhood asthma.…”
Section: Discussionmentioning
confidence: 99%
“…De los 10 expedientes que finalmente se incluyeron, 6 eran varones y 4 mujeres, la edad media de la muestra fue de 10 ± 2 años, con un peso medio de 24 ± 10 kilogramos y una talla media de 130 ± 14 centímetros. Con respecto a los biomarcadores inflamatorios en asma (8,9) mostraban valores similares a los que utilizamos en nuestra unidad que son los descritos por Hsu HK et.al. (15) Al interpretar datos espirométricos, un hábito común en medicina respiratoria es expresar los valores medidos como porcentaje del valor predictivo.…”
Section: Resultsunclassified
“…(15) Al interpretar datos espirométricos, un hábito común en medicina respiratoria es expresar los valores medidos como porcentaje del valor predictivo. Siendo la regla válida sólo si la dispersión alrededor del valor predictivo es proporcional a ese valor, en consecuencia, es grande si el valor predicho es grande y proporcionalmente más pequeño si el valor predicho es menor (9). Debido a que no existe tal proporcionalidad, el uso del porcentaje del valor predictivo llevará inevitablemente a una interpretación errónea de los resultados.…”
Section: Resultsunclassified
See 1 more Smart Citation
“…FE NO measurements help in asthma diagnosis if taken together with the clinical history; FE NO also assists in evaluating the therapeutic response to oral or inhaled corticosteroids and predicts disease exacerbations after treatment withdrawal (29). Because FE NO is a phenotype-linked biomarker, it is suited for monitoring children on biological therapy (30). A recent systematic review and meta-analysis support the diagnostic accuracy of FE NO testing in pediatric asthma (31).…”
Section: Exhaled Nitric Oxide (No)mentioning
confidence: 99%